相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress
Mariette H. W. Kappers et al.
HYPERTENSION (2012)
Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension
Kazufumi Nakamura et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2012)
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
R. A. Larson et al.
LEUKEMIA (2012)
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
Karl J. Aichberger et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Imatinib Mesylate-Incorporated Nanoparticle-Eluting Stent Attenuates In-Stent Neointimal Formation in Porcine Coronary Arteries
Seigo Masuda et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2011)
Severe Peripheral Arterial Disease During Nilotinib Therapy
Philipp Le Coutre et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2011)
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
Thomas Force et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
Paul W. Manley et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
The Peripheral Arterial disease study (PERART/ARTPER): prevalence and risk factors in the general population
Maria Teresa Alzamora et al.
BMC PUBLIC HEALTH (2010)
Increased Cell and Matrix Accumulation During Atherogenesis in Mice With Vessel Wall-Specific Deletion of Discoidin Domain Receptor 1
Christopher Franco et al.
CIRCULATION RESEARCH (2010)
Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
Hui Cheng et al.
CIRCULATION RESEARCH (2010)
Imatinib Mesylate Has The Potential to Exert Its Efficacy by Down-Regulating The Plasma Concentration of Platelet-Derived Growth Factor in Patients With Pulmonary Arterial Hypertension
Masaru Hatano et al.
INTERNATIONAL HEART JOURNAL (2010)
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management
Jeffrey W. Olin et al.
MAYO CLINIC PROCEEDINGS (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice
Nicole M Agostino et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Discoidin Domain Receptor-1 Deficiency Attenuates Atherosclerotic Calcification and Smooth Muscle Cell-Mediated Mineralization
Pamela J. Ahmad et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Discoidin Domain Receptor 1 on Bone Marrow-Derived Cells Promotes Macrophage Accumulation During Atherogenesis
Christopher Franco et al.
CIRCULATION RESEARCH (2009)
Discoidin domain receptor 1 (Ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice
Christopher Franco et al.
CIRCULATION RESEARCH (2008)
High prevalence of peripheral arterial disease in HIV-infected persons
Daniel Periard et al.
CLINICAL INFECTIOUS DISEASES (2008)
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Manuela Schmidinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells
Li Li et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (Lower extremity, renal, mesenteric, and abdominal aortic): Executive summary
AT Hirsch et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Imatinib attenuates diabetes-associated atherosclerosis
M Lassila et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Prevalence of and risk factors for peripheral arterial disease in the United States - Results from the National Health and Nutrition Examination Survey, 1999-2000
E Selvin et al.
CIRCULATION (2004)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Peripheral arterial disease detection, awareness, and treatment in primary care
AT Hirsch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: A longitudinal study
JD Hooi et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2001)
分享论文
